[Atrial fibrillation in old age: risk management and features of the use of direct oral anticoagulants].

Senile patients with atrial fibrillation (AF) are at a higher risk of thromboembolism and hemorrhage than younger patients. Three direct oral anticoagulants (DOAC), apixaban, dabigatran, and rivaroxaban, are registered in the Russian Federation and are extensively used for prevention of stroke in patients with AF. The DOAC treatment of older patients requires considering peculiarities of these patients, clinical situation and properties of individual drugs to achieve the balance of efficiency and safety and a comprehensive protection.

[Recommendations for the management of COVID 19 patients regarding proarrhythmic effects of some current treatments, specifically if these patients suffer from arrhythmias, and for those receiving antiarrhythmic therapy.].

Recommendation provides information to employees of medical departments at any level and primarily primary care about the possible proarrhythmic and adverse effects of drugs used for the treatment of COVID-19 patients and the features of therapy for COVID-19 patients with heart rhythm and conduction disorders receiving permanent antiarrhythmic therapy.

[Use of Statins, Anticoagulants, Antiaggregants and Antiarrhythmic Drugs in Patients With COVID-19. The Agreed Experts' Position of Russian Society of Cardiology, Eurasian Association of Therapists, National Society on Atherothrombosis, Societies of Experts in Urgent Cardiology, Eurasian Arrhythmology Association].

This article discusses relevant aspects in the treatment of patients with COVID-19. Up-to-date information about principles for administration of statins, antithrombotics, and antiarrhythmics is presented. The authors addressed in detail specific features of reversing heart rhythm disorders in patients with coronavirus infection and the interaction of antiarrhythmic and antiviral drugs.

[Combined Antithrombotic Therapy in Patients with a Stable Atherosclerotic Cardiovascular Diseases: What Direction did COMPASS Show?].

In patients with stable ischemic heart disease (IHD) and/or peripheral artery disease (PAD), current secondary prevention, including the antiplatelet monotherapy, is associated with a significant residual risk of recurrent cardiovascular complications (CVC). Practical application of results from many modern studies evaluating the effect of secondary prevention of atherothrombosis is complicated. An additional influence on coagulation may play a key role in prevention of atherothrombosis.

[How to maintain an adherence to oral anticoagulant in a patient with atrial fibrillation?].

Less onerous, compared with warfarin, treatment with direct oral anticoagulants (DOA) can lead to better adherence to treatment of patients with atrial fibrillation (AF). However, in a certain number of patients with AF, who were recommended by DOA, cardioembolic stroke recurs, which is largely due to the patients' failure to comply with medical recommendations. The appointment of DOA as first-line drugs does not guarantee a high adherence of patients with non-valvular AF.

[Treatment of Patients with Stable Manifestations of Atherosclerotic Vascular Disease: New Possibilities (Conclusion of the Council of Experts from November 16, 2018, Rostov-on-Don)].

In the conclusion of the council of experts (list of participants see text) the following issues are discussed: regional specifics of diagnostics and therapy of patients with ischemic heart disease (IHD) and / or peripheral arterial disease (PAD), methods of risk assessment in patients with stable course of atherosclerotic disease, pathogenetic validity of simultaneous inhibition of coagulation and platelet thrombus formation, as well as clinical significance of a novel therapeutic approach - combined use of rivaroxaban and acetylsalicylic acid (ASA). Possible problems and ways to their solution at implementation in clinical practice of the novel scheme of antithrombotic therapy are presented. Importance of multidisciplinary approach to management of patients with IHD and concomitant diseases is stressed.

[Not Available].

A report was presented on all four Hot Line: Late-Breaking Clinical Trials sessions of the European Society of Cardiology Congress 2017 on the results of new clinical research in cardiology.

[Treatment of Patients With Atrial Fibrillation: the Search for Optimal Solutions].

Atrial fibrillation (AF) - the most common arrhythmia in clinical practice, impair the quality of life significantly increases morbidity and mortality. Current methods of treatment of patients with AF, except anticoagulant therapy hitherto failed to provide significant improvement in cardiovascular events are of limited effectiveness and cause significant side effects. The article presents the current opportunities and challenges for the treatment of patients with atrial fibrillation.

[Comparison of Verapamil and Amlodipine for Treatment of Chronic Heart Failure With Preserved Left Ventricular Ejection Fraction in Patients With Hypertensive Disease].

Objective: to compare efficacy of verapamil and amlodipine in treatment of chronic heart failure (CHF) with preserved left ventricular (LV) ejection fraction (EF) in patients with hypertensive disease (HD).

Material And Methods: Patients with stage III HD, class II-III CHF, and LVEF more or equal 50% (n=167, age 48-70 years) underwent complex examination before and after 12 months of treatment with perindopril combined either with verapamil SR (n=85) or amlodipine (n=82).

Results: Average 6-minute walk distance increased after both verapamil and amlodipine containing treatment (by 15.

[Triple antianginal combinations in the treatment of elderly and senile patients with stable angina].

Aim: To compare the efficiency and safety of antianginal therapy (AAT) using a combination of bisoprolol, ivabradine, and trimetazidine or ranolazine in elderly and senile patients with stable angina.

Subjects And Methods: The study enrolled 107 patients aged 60 to 79 years with coronary heart disease and Functional Class II and III angina. When the patients taking bisoprolol 1.

[Heart Rate and Cardioprotection: New Data and Perspectives].

The article presents the results of new experimental and clinical studies of selective inhibitor of If-channel, ivabradine confirming the feasibility of its use in coronary heart disease and chronic heart failure. We discuss some of the pleiotropic effects of ivabradine. Ivabradine may be useful in therapeutic areas outside those where it has previously demonstrated clinical efficacy.

[Congress of the European Society of Cardiology (Barcelona, 2014): Results of Most Important Clinical Studies].

This brief report on the European Society of Cardiology Congress 2014 contains detailed reflection of results of international studies presented at 5 Hot Line scientific sessions.

[ADVANCE-ON Trial; How to Achieve Maximum Reduction of Mortality in Patients With Type 2 Diabetes].

Of 10,261 patients with type 2 diabetes who survived to the end of a randomized ADVANCE trial 83% were included in the ADVANCE-ON project for observation for 6 years. The difference in the level of blood pressure which had been achieved during 4.5 years of within trial treatment with fixed perindopril/indapamide combination quickly vanished but significant decrease of total and cardiovascular mortality in the group of patients treated with this combination for 4.

[Congress of European society of cardiology (amsterdam, 2013): new recommendations and most important clinical studies].

In this review we present short report on European Congress of Cardiology which took place in Amsterdam from August 3 to September 4, 2013. Four new European recommendations on the treatment of cardiovascular diseases are briefly characterized and reports of Hot Line and Clinical Trial Update scientific sessions are presented.

[Antiarrhythmic therapy in patients with paroxysmal and persistent atrial fibrillation: identification of achievable goals and assessment of available funds].

One of the achievable goals of treatment of patients with paroxysmal and persistent atrial fibrillation should be to prevent the progression to permanent form of arrhythmia, which is associated with an increased risk of complications and worsening prognosis. The review presents easily identifiable predictors of progression of atrial fibrillation, reviews the available treatment options and their effectiveness and safety.

[ATLANTIC trial and feasibility of early administration of ticagrelor in myocardial infarction].

The ATLANTIC trial compared effects of initiation of ticagrelor at the prehospital (ambulance) or hospital (in the catheterization laboratory) stage of treatment of patients with ST-segment elevation myocardial infarction. Initiation of therapy with ticagrelor at prehospital stage short before percutaneous coronary intervention was safe, but did not improve coronary reperfusion before this procedure. However, earlier administration of ticagrelor significantly reduced the risk of stent thrombosis after percutaneous coronary intervention.

[Results of large clinical studies presented at the European Society of Cardiology Congress 2012].

The article contains short characteristics of 6 novel European guidelines on the treatment of cardiovascular diseases and accounts of main scientific sessions (Hot Line, Clinical Trial and Registry Update) of the European Society of Cardiology Congress 2012.

[Blockers of renin-angiotensin-aldosterone system in the treatment of arterial hypertension: classics versus the modern].

According to results of large clinical studies angiotensin II receptor blockers (ARB) and aliskiren do not lower risk of cardiovascular complications and mortality in wide spectrum of clinical conditions and are able to worsen renal outcomes. It is expedient to prefer inhibitors of angiotensin converting enzyme in particular perindopril over ARB in the treatment of patients with arterial hypertension taking into consideration differences in effect on mortality. Fixed perindopril/indapamide combination provides achievement of target arterial pressure in many patients with uncontrolled hypertension, has good tolerability, is metabolically neutral, and possesses high organoprotective properties.

[Anticoagulants in the prevention of complications in patients with atrial fibrillation].

This review presents new data on the comparative effectiveness and safety of treatment with oral anticoagulants warfarin, dabigatran, rivaroxaban, apixaban for prevention of thromboembolism in patients with atrial fibrillation.

[Antihypertensive therapy and dynamics of vascular wall rigidity in elderly patients with non-valvular atrial fibrillation].

This comparative ultrasound study included 210 patients aged 65-80 years with non-valvular atrial fibrillation treated with the use of 4 different therapeutic modalities. Intake of perindopril, valsartan, valsartan + rozuvastatin, and lercanidipine resulted in a rise in distension index of common carotid artery, decrease of rigidity coefficient of the aortic wall and increase of the pulsed wave propagation speed. Combination of valsartan (80-160 mg/d) and rozuvastatin (10 mg/d) had the most pronounced effect on the vascular wall compliance compared with other modalities and reduced the frequency of ischemic stroke, myocardial infarction, and mortality.

[Quantitative characteristic of the regulatory and adaptive status for the estimation of severity of chronic cardiac failure].

A method for the estimation of severity of chronic cardiac failure (CCF) based on the quantitative evaluation of the regulatory and adaptive status (RAS) of the organism. Patients with FC I-III HCF concomitant with grade I-III hypertensive disease and/or coronary heart disease underwent cardiorespiratory synchronism test for the quantitative estimation of RAS (6 min walk), echocardiography, treadmill measuring maximum oxygen consumption (VO2max), measurement of plasma N-terminal precursor of brain natriuretic peptide. The lowering of RAS was especially pronounced when HCF FC changed from I to III, in agreement with results of traditional instrumental and laboratory tests.

[Modern drug therapy of atrial fibrillation: selection of treatment strategy, antiarrhythmic preparations, and schemes of treatment].

This review presents novel literature data on drug treatment of atrial fibrillation. We discuss here choice of strategy of therapy, antiarrhythmic drugs, and algorithms of preventive measures aimed at prevention of recurrences of this arrhythmia.

[Effect of various types of antihypertensive therapy on elasticity of arterial wall in elderly patients with hypertensive disease and nonvalvular atrial fibrillation].

Basing on the data of ultrasound study we compared effects of various antihypertensive therapies on elastic properties of common carotid arteries and the thoracic aorta in 133 patients aged 65-80 years with nonvalvular atrial fibrillation (AF). The use of perindopril, lercanidipin, valsartan and its combination with rosuvastatin was associated with elevation of the distensibility index of common carotid artery and lowering of coefficient of stiffness of aortic wall compared with the initial state. Combination of valsartan (80-160 mg/day) with rosuvastatin 10 (mg/day) produced most pronounced effect on compliance of vascular wall compared with other variants of treatment.